

-4- (Fourth amended)

e1 A composition comprising an isolated 16 (± 4) kDa *Sarcocystis neurona* antigen and an isolated 30 (± 4) kDa *Sarcocystis neurona* antigen in a pharmaceutically accepted carrier.

-13- (Twice amended)

A method for treating an equine with a *Sarcocystis neurona* infection comprising:

5 (a) providing a composition consisting essentially of an isolated 16 (± 4) kDa antigen and an isolated 30 (± 4) kDa antigen of *Sarcocystis neurona* in a pharmaceutically accepted carrier; and
e2

(b) inoculating the equine with the composition to treat the equine with the *Sarcocystis neurona* infection.

-45- (Twice amended)

5 e3 A method for treating a disease in an equine caused by a *Sarcocystis neurona* infection which comprises providing a composition which when injected into the equine causes the equine to produce antibodies against a 16 (± 4) kDa antigen and a 30 (± 4) kDa antigen of the *Sarcocystis neurona* which treats the disease caused by the *Sarcocystis neurona*.

-46- (Amended)

e3
Ant The method of Claim 45 wherein the composition comprises an isolated 16 (± 4) kDa antigen and an isolated 30 (± 4) kDa antigen in a pharmaceutically accepted carrier.

-50- (Amended)

CH The method of Claim 45 wherein the composition is administered by an inoculation route selected from the group consisting of intranasal administration, intramuscular injection, intraperitoneal injection, intradermal injection, and subcutaneous injection.
